Literature DB >> 25248599

Long-term effects of treatment of pituitary adenomas.

Alberto M Pereira1.   

Abstract

Pituitary adenomas can be treated effectively in the vast majority of cases. After successful treatment for pituitary disease, many patients still report reduced quality of life in the presence of persistent morbidity and (slightly) increased mortality. At present, there is an increasing awareness that in many cases long-term remission of functioning or nonfunctioning adenomas does not equal cure. The causes are most probably multifactorial. Hypopituitarism, intrinsic imperfections of surgical or endocrine replacement therapy, but also persistent effects of treatment and of previous hormone excess on the central nervous system all affect long-term morbidity, general well-being, and mortality. This implies that treatment goals for patients with pituitary adenomas will shift from long-term cure to long-term care. Further research is therefore needed to get more insight into each of these factors of influence, such as the extent of reversibility of hormone excess syndromes on cardiovascular risk and behavior. The fact that coping strategies, despite long-term remission, are altered and illness perceptions are affected strongly suggests that long-term care should incorporate self-management interventions that might help to improve quality of life for patients.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Long-term effects; hormone replacement; hypothalamic dysfunction; morbidity; mortality; pituitary adenoma; quality of life

Mesh:

Year:  2014        PMID: 25248599     DOI: 10.1016/B978-0-444-59602-4.00024-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  6 in total

1.  Neuropsychological functioning in acromegaly: towards identification of modifiable factors to improve long-term care after remission.

Authors:  Alberto M Pereira
Journal:  Endocrine       Date:  2015-09-08       Impact factor: 3.633

Review 2.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.

Authors:  Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years.

Authors:  Elizabeth M Ward; Recinda L Sherman; S Jane Henley; Ahmedin Jemal; David A Siegel; Eric J Feuer; Albert U Firth; Betsy A Kohler; Susan Scott; Jiemin Ma; Robert N Anderson; Vicki Benard; Kathleen A Cronin
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery.

Authors:  Stephanie E Baldeweg; Hani Joseph Marcus; Elika Karvandi; John Gerrard Hanrahan; Danyal Zaman Khan; Pierre-Marc Boloux; Fion Bremner; Ivan Cabrilo; Neil Dorward; Joan Grieve; Sue Jackson; Glenda Jimenez; Inma Serrano; Victoria Anne Nowak; Angelos Kolias
Journal:  Pituitary       Date:  2022-07-15       Impact factor: 3.599

5.  A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.

Authors:  Shousen Wang; Biao Li; Chenyu Ding; Deyong Xiao; Liangfeng Wei
Journal:  Oncotarget       Date:  2017-03-07

6.  T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.

Authors:  Sheng Zhong; Bo Wu; Jiahui Li; Xinhui Wang; Shanshan Jiang; Fangfei Hu; Gaojing Dou; Yuan Zhang; Chunjia Sheng; Gang Zhao; Yunqian Li; Yong Chen
Journal:  Aging (Albany NY)       Date:  2019-10-26       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.